1 Recent advances in nanocarrier-based targeted drug delivery: For lung, colon, and breast cancers https://www.jourcc.com/index.php/jourcc/article/view/jcc523 10.61186/jcc.5.2.3 1 For a while now, the development of research and technology has provided us with different approaches which show how cancer works and how is it possible to develop different methods of treatment. Nanotechnology and nano-carriers have shown a promising approach toward the treatment of different types of cancer. Nano-carriers based targeted drug delivery have different forms such as lipid-based, polymeric-based, inorganic-based, and hybrid-based, each of them is unique in structure, size, “function and” ability to deliver the drugs. Therapeutic substances can be used with the help of the applied modifications to the nano-carriers. These particles have shown significant benefits such as effectiveness, safety, low toxicity, biocompatibility, biodegradability and the improved quality of the treatment. The therapeutic properties of the nano-carriers can be regulated. This can help to provide an effective treatment for a patient with a specific diagnosed disease. The treatments can be administered either orally, intravenously or by combined route. The overall results of the use of nano-carriers have certainly created an interesting approach and created an opportunity for new treatments that improve the patient’s profile. 74 90 Parisa Sabouri Medical University of Science, Shiraz Iran Parisa.sabouri.md@gmail.com Sogand Bahadori Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman Iran Sogolbahadori@gmail.com Azam Mohsennejadesaniyani Department of Midwifery, Shool of Medicine, Qom University of Medical Sciences, Qom Iran azammohsennejad@gmail.com Seyed Mohammad Reza Hosseini School of medicine, Zanjan University of Medical Sciences, Zanjan Iran Hosseini-md@outlook.com Mahbod Khodamorovati Faculty of Medicine, The University of Georgia, Tbilisi Georgia dr.mahbodmd22@gmail.com Erfan Yazdani School of Medicine, North Khorasan University of Medical Sciences, Bojnord Iran e.yazdani@nkums.ac.ir Dina Mohammadi Department of Mechanics and Industries, Islamic Azad University, Qazvin Branch, Qazvin Iran Dina_mohammadi@yahoo.com Darya Nejadkoorki Faculty of Medicine, Yazd Medical University, Yazd Iran daryanejad2004@gmail.com Marika Sulashvili School of Science and Technology, University of Georgia, Tbilisi Georgia marisula25@gmail.com Ketevan Tavamaishvili Georgian American University, 10 Merab Aleksidze street, Tbilisi 0160 Georgia ketevan.tavamaishvili@gau.edu.ge Husain AbdulSattar Department of Medicine, School of health science, The University of Georgia, Tbilisi 0171 Georgia husain.abdulla02@gmail.com Johan James John Department of Medicine, School of health science, The University of Georgia, Tbilisi 0171 Georgia johanjames2004@gmail.com Joen James John Department of Medicine, School of health science, The University of Georgia, Tbilisi 0171 Georgia joenjames2004@gmail.com Lili Arabuli Arabuli School of Science and Technology, University of Georgia, Tbilis Georgia l.arabuli@ug.edu.ge Khatuna Vashakmadze Department of Medicine, University of Georgia, Tbilisi Georgia Kha.vashakmadze@ug.edu.ge Drug delivery Nanocarriers Lung cancer Colon cancer Breast Cancer Article3.pdf [1] E. Huynh, B.Y. Leung, B.L. Helfield, M. Shakiba, J.-A. Gandier, C.S. Jin, E.R. Master, B.C. Wilson, D.E. Goertz, G. Zheng, In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging, Nature nanotechnology 10(4) (2015) 325-332.##[2] J.M. Keca, J. Chen, M. Overchuk, N. Muhanna, C.M. MacLaughlin, C.S. Jin, W.D. Foltz, J.C. Irish, G. Zheng, Nanotexaphyrin: One‐Pot Synthesis of a Manganese Texaphyrin‐Phospholipid Nanoparticle for Magnetic Resonance Imaging,Angewandte Chemie International Edition 55(21) (2016) 6187-6191. ##[3] J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, International journal of cancer 127(12) (2010) 2893-2917. ##[4] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, CA: a cancer journal for clinicians 61(2) (2011) 69-90.##[5] R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, D. Cooper, T. Gansler, C. Lerro, S. Fedewa, Cancer treatment and survivorship statistics, 2012,CA: a cancer journal for clinicians 62(4) (2012) 220-241.##[6] Y. Ma, L. Huang, C. Song, X. Zeng, G. Liu, L. Mei, Nanoparticle formulation of poly(ɛ-caprolactone-co-lactide) -d-α-tocopheryl polyethyleneglycol 1000 succinate random copolymer for cervical cancer treatment, Polymer 51(25) (2010) 5952-5959.##[7] R. Labianca, G.D. Beretta, B. Kildani, L. Milesi, F. Merlin, S. Mosconi, M.A. Pessi, T. Prochilo, A. Quadri, G. Gatta, F. de Braud, J. Wils, Colon cancer, CriticalReviews in Oncology/Hematology 74(2) (2010) 106-133.##[8] R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA: a cancer journal for clinicians 63(1) (2013) 11-30.##[9] R.A. Baan,Carcinogenic hazards from inhaled carbon black, titanium dioxide, and talc not containing asbestos or asbestiform fibers: recent evaluations by an IARC Monographs Working Group, Inhalation toxicology 19(sup1) (2007) 213-228. ##[10] M. Quintero Escobar, M. Maschietto, A.C. Krepischi, N. Avramovic, L. Tasic, Insights into the chemical biology of childhood embryonal solid tumors by NMR-based metabolomics, Biomolecules 9(12) (2019) 843. ##[11] T. Radic, V. Coric, Z.Bukumiric, M. Pljesa-Ercegovac, T. Djukic, N. Avramovic, M. Matic, S. Mihailovic, D. Dragicevic, Z. Dzamic, GSTO1* CC genotype (rs4925) predicts shorter survival in clear cell renal cell carcinoma male patients, Cancers 11(12) (2019) 2038.##[12] P.Y. Liyanage, S.D. Hettiarachchi, Y. Zhou, A. Ouhtit, E.S. Seven, C.Y. Oztan, E. Celik, R.M. Leblanc, Nanoparticle-mediated targeted drug delivery for breast cancer treatment, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1871(2) (2019) 419-433.##[13] E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, An-aplastic thyroid carcinoma: treatment outcome and prognostic factors, Cancer 103(7) (2005) 1330-1335. ##[14] P. Vega-Vásquez, N.S. Mosier, J. Irudayaraj, Nanoscale drug delivery sys-tems: from medicine to agriculture, Frontiers in Bioengineering and Biotechnol-ogy 8 (2020) 79. ##[15] A.M. Vargason, A.C. Anselmo, S. Mitragotri, The evolution of commercial drug delivery technologies, Nat Biomed Eng 5(9) (2021) 951-967.##[16] C. Li, J. Wang, Y. Wang, H. Gao, G. Wei, Y. Huang, H. Yu, Y. Gan, Y. Wang,L. Mei, Recent progress in drug delivery, Acta pharmaceutica sinica B 9(6) (2019) 88P. 1145-1162. ## [17] Z. Zhang, J. Guan, Z. Jiang, Y. Yang, J. Liu, W. Hua, Y. Mao, C. Li, W. Lu, J. Qian, Brain-targeted drug delivery by manipulating protein corona functions, Nature Communications 10(1) (2019) 3561.##[18] M.V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, R.M. O’Regan, Emerging use of nanoparticles in diagnosis and treatment of breast cancer, The lancet oncology 7(8) (2006) 657-667. ##[19] E.M. Jaffee, C. Van Dang, D.B. Agus, B.M. Alexander, K.C. Anderson, A. Ashworth, A.D. Barker, R. Bastani, S. Bhatia, J.A. Bluestone, Future cancer research priorities in the USA: a Lancet Oncology Commission, The Lancet Oncology 18(11) (2017) e653-e706.##[20] G. Poste, R. Kirsh, Site–specific (targeted) drug delivery in cancer therapy,Bio/Technology 1(10) (1983) 869-878. ##[21] F.U. Din, W. Aman, I. Ullah, O.S. Qureshi, O. Mustapha, S. Shafique, A. Zeb, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, International journal of nanomedicine (2017) 7291-7309.##[22] Z. Li, S. Tan, S. Li, Q. Shen, K. Wang, Cancer drug delivery in the nano era: An overview and perspectives, Oncology reports 38(2) (2017) 611-624.##[23] D. Zamarin, J.D. Wolchok, Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer, Molecular Therapy-Oncolytics1 (2014).#3[24] S. Liu, Epigenetics advancing personalized nanomedicine in cancer therapy, Advanced drug delivery reviews 64(13) (2012) 1532-1543.##[25] R. Sinha, G.J. Kim, S. Nie, D.M. Shin, Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery, Molecular cancer therapeutics 5(8) (2006) 1909-1917.##[26] M.F. Zaky, Y.L. Youssef, M.A. Megahed, Impact of Surface Design and Coating on The Efficacy of Nano-Carriers as Drug Delivery Systems: A Review, ERU Research Journal (2023).##[27] S. Senapati, A.K. Mahanta, S. Kumar, P. Maiti, Controlled drug delivery vehicles for cancer treatment and their performance, Signal transduction and targetedtherapy 3(1) (2018) 7.##[28] L. Abarca-Cabrera, P. Fraga-García, S. Berensmeier, Bio-nano interactions: binding proteins, polysaccharides, lipids and nucleic acids onto magnetic nanoparticles, Biomaterials research 25 (2021) 1-##[29] Y. Duan, A. Dhar, C. Patel, M. Khimani,S. Neogi, P. Sharma, N.S. Kumar, R.L. Vekariya, A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems, RSC advances 10(45) (2020) 26777-26791.##[30] M.S.B. Reddy, D. Ponnamma, R. Choudhary, K.K. Sadasivuni, A comparative review of natural and synthetic biopolymer composite scaffolds, Polymers 13(7)(2021) 1105. ##[31] S. Sheoran, S. Arora, G. Pilli, Lipid Based Nanoparticles For Treatment Of Cancer, Heliyon (2022) e09403. ##[32] P.C. Lyon, M.D. Gray, C. Mannaris, L.K. Folkes, M. Stratford, L. Campo, D.Y. Chung, S. Scott, M. Anderson, R. Goldin, Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial, The Lancet Oncology 19(8) (2018) 1027-1039.##[33] S. Aghamiri, A. Jafarpour, M.M. Gomari, J. Ghorbani, M. Rajabibazl, Z. Payandeh, siRNA nanotherapeutics: a promising strategy for anti‐HBV therapy,IET Nanobiotechnology 13(5) (2019) 457-463. ##[34] B. Ghanbarzadeh, A. Babazadeh, H. Hamishehkar, Nano-phytosome as a po-tential food-grade delivery system, Food bioscience 15 (2016) 126-135.##[35] S. Tran, P.-J. DeGiovanni, B. Piel, P. Rai, Cancer nanomedicine: a review of recent success in drug delivery, Clinical and translational medicine 6 (2017) 1-21.##[36] C.H. Albertsen, J.A. Kulkarni, D. Witzigmann, M. Lind, K. Petersson, J.B. Simonsen, The role of lipid components in lipid nanoparticles for vaccines and gene therapy, Advanced Drug Delivery Reviews 188 (2022) 114416. ## [37] S. Simões, A. Filipe, H. Faneca, M. Mano, N. Penacho, N. Düzgünes, M. Pedroso de Lima, Cationic liposomes for gene delivery, Expert opinion on drug delivery 2(2) (2005) 237-254.##[38] A. Sharma, D. Shambhwani, S. Pandey, J. Singh, H. Lalhlenmawia, M. Ku- marasamy, S.K. Singh, D.K. Chellappan, G. Gupta, P. Prasher, K. Dua, D. Kumar, Advances in Lung Cancer Treatment Using Nanomedicines, ACS Omega 8(1) (2023) 10-41.##[39] R.K. Harwansh, S. Bahadur, R. Deshmukh, M.A. Rahman, Exciting potential of nanoparticlized lipidic system for effective treatment of breast cancer and clinical updates: A translational prospective, Current pharmaceutical design 26(11) (2020) 1191-1205.##[40] S. Gadag, S. Sinha, Y. Nayak, S. Garg, U.Y. Nayak, Combination therapy and nanoparticulate systems: Smart approaches for the effective treatment of breast cancer, Pharmaceutics 12(6) (2020) 524.##[41] M.-Y. Wong, G.N. Chiu, Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model, Nanomedicine: Nanotechnology, Biology and Medicine 7(6) (2011) 834-840. ##[42] J.-Q. Chen, J. Russo, ERα-negative and triple negative breast cancer: molecular features and potential therapeutic approaches, Biochimica et Biophysica Acta(BBA)-Reviews on Cancer 1796(2) (2009) 162-175.##[43] B. Haley, E. Frenkel, Nanoparticles for drug delivery in cancer treatment,Urologic Oncology: Seminars and original investigations, Elsevier, 2008, pp. 57-64.## [44] G. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, J. Stathopoulos, A. Provata, P. Yiamboudakis, D. Veldekis, Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-celllung cancer: a randomized phase III multicenter trial, Annals of Oncology 21(11) (2010) 2227-2232.##[45] M. Palmer, J. Parker, S. Modi, C. Butts, M. Smylie, A. Meikle, M. Kehoe,G. MacLean, M. Longenecker, Phase I study of the BLP25 (MUC1 Peptide) lipo- somal vaccine for active specific immunotherapy in stage IIIB/IV non–small-cell lung cancer, Clinical lung cancer 3(1) (2001) 49-57.## [46] G.H. Petersen, S.K. Alzghari, W. Chee, S.S. Sankari, N.M. La-Beck, Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin, Journal of controlledrelease 232 (2016) 255-264.## [47] L. Cheng, F.-Z. Huang, L.-F. Cheng, Y.-Q. Zhu, Q. Hu, L. Li, L. Wei, D.-W. Chen, GE11-modified liposomes for non-small cell lung cancer targeting: prepara-tion, ex vitro and in vivo evaluation, International journal of nanomedicine (2014) 921-935.##[48] A. Thomas, B.A. Teicher, R. Hassan, Antibody–drug conjugates for cancer therapy, The Lancet Oncology 17(6) (2016) e254-e262. [49] K. Shroff, E. Kokkoli, PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells, Langmuir 28(10) (2012) 4729-4736. ##[50] D. Cao, X. Zhang, M. Akabar, Y. Luo, H. Wu, X. Ke, T. Ci, Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer, Artificial cells, nanomedicine, and biotechnology 47(1) (2019) 181-191.##[51] L. Gkionis, R.A. Campbell, H. Aojula, L.K. Harris, A. Tirella, Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity, International Journal of Pharmaceutics 590 (2020) 119926.##[52] X.-j. Kang, H.-y. Wang, H.-g. Peng, B.-f. Chen, W.-y. Zhang, A.-h. Wu, Q. Xu, Y.-z. Huang, Codelivery of dihydroartemisinin and doxorubicin in mannosylatedliposomes for drug-resistant colon cancer therapy, Acta Pharmacologica Sinica38(6) (2017) 885-896.##[53] N. Avramović, B. Mandić, A. Savić-Radojević, T. Simić, Polymeric nanocarriers of drug delivery systems in cancer therapy, Pharmaceutics 12(4) (2020) 298.[54] Y. Zhang, H. Zhang, X. Wang, J. Wang, X. Zhang, Q. Zhang, The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles, Biomaterials 33(2) (2012) 679-691. ##[55] L. Liu, L. Sun, Q. Wu, W. Guo, L. Li, Y. Chen, Y. Li, C. Gong, Z. Qian, Y.Wei, Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis, International journal of pharmaceutics 443(1-2)(2013) 175-182.##[56] S.E. Kim, I.C. Kwon, H.-R. Song, K. Park, Insight of key factors influencing tumor targeting characteristics of Glycol Chitosan-based nanoparticles and in vivo applications, Macromolecular Research 20 (2012) 1109-1117.#3[57] K. Kim, M. Lee, H. Park, J.-H. Kim, S. Kim, H. Chung, K. Choi, I.-S. Kim, B.L. Seong, I.C. Kwon, Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging, Journal of the American Chemical Society 128(11)(2006) 3490-3491.#3[58] A. Sharma, N. Jain, R. Sareen, Nanocarriers for diagnosis and targeting of breast cancer, BioMed research international 2013 (2013).##[59] H. Zhang, B. Chen, H. Jiang, C. Wang, H. Wang, X. Wang, A strategy for ZnO nanorod mediated multi-mode cancer treatment, Biomaterials 32(7) (2011) 1906-1914.##[60] P. Wang, X.-H. Zhao, Z.-Y. Wang, M. Meng, X. Li, Q. Ning, Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment, Cancer letters 298(1) (2010) 34-49.##[61] L. Ray, Chapter 4 - Polymeric Nanoparticle-Based Drug/Gene Delivery for Lung Cancer, in: P. Kesharwani (Ed.), Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer, Academic Press2019, pp. 77-93.##[62] Y. Yang, W.S. Cheow, K. Hadinoto, Dry powder inhaler formulation of lipid– polymer hybrid nanoparticles via electrostatically-driven nanoparticle assemblyonto microscale carrier particles, International journal of pharmaceutics 434(1-2) (2012) 49-58.##[63] X. You, Y. Kang, G. Hollett, X. Chen, W. Zhao, Z. Gu, J. Wu, Polymeric nanoparticles for colon cancer therapy: overview and perspectives, Journal of Materials Chemistry B 4(48) (2016) 7779-7792.##[64] S. Srinivasa-Gopalan, K. Yarema, Nanotechnologies for the life sciences: dendrimers in cancer treatment and diagnosis, Nanotechnologies for the Life Sci7 (2007).##[65] D.A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, P. Smith, A new class of polymers: starburst-dendritic macromolecules, Polymer journal 17(1) (1985) 117-132.#3[66] G.R. Newkome, Z. Yao, G.R. Baker, V.K. Gupta, Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol, The Journal of Organic Chemistry 50(11) (1985) 2003-2004.##[67] E. Abbasi, S.F. Aval, A. Akbarzadeh, M. Milani, H.T. Nasrabadi, S.W. Joo, Y. Hanifehpour, K. Nejati-Koshki, R. Pashaei-Asl, Dendrimers: synthesis, applications, and properties, Nanoscale research letters 9(1) (2014) 1-10.##[68] M.K. Bhalgat, J.C. Roberts, Molecular modeling of polyamidoamine (PAMAM) Starburst™ dendrimers, European polymer journal 36(3) (2000) 647-651.##[69] S.E. Stiriba, H. Frey, R. Haag, Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy, Angewandte Chemie International Edition 41(8) (2002) 1329-1334.##[70] D.A. Tomalia, J.M. Fréchet, Discovery of dendrimers and dendritic polymers: A brief historical perspective, Journal of Polymer Science Part A: Polymer Chemistry 40(16) (2002) 2719-2728.##[71] J.B. Wolinsky, M.W. Grinstaff, Therapeutic and diagnostic applications of dendrimers for cancer treatment, Advanced drug delivery reviews 60(9) (2008) 1037-1055.## [72] S. Svenson, D.A. Tomalia, Dendrimers in biomedical applications—reflections on the field, Advanced drug delivery reviews 64 (2012) 102-115.##[73] G. Spataro, F. Malecaze, C.-O. Turrin, V. Soler, C. Duhayon, P.-P. Elena, J.-P. Majoral, A.-M. Caminade, Designing dendrimers for ocular drug delivery, European journal of medicinal chemistry 45(1) (2010) 326-334.##[74] P. Parhi, C. Mohanty, S.K. Sahoo, Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy, Drug discovery today 17(17-18) (2012) 1044-1052.##[75] W. Tao, X. Zeng, T. Liu, Z. Wang, Q. Xiong, C. Ouyang, L. Huang, L. Mei,Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy, Acta Biomater 9(11) (2013) 8910-20.##[76] M.R. Nabid, S.J. Tabatabaei Rezaei, R. Sedghi, H. Niknejad, A.A. Entezami, H.A. Oskooie, M.M. Heravi, Self-assembled micelles of well-defined pentaerythritol-centered amphiphilic A4B8 star-block copolymers based on PCL and PEG for hydrophobic drug delivery, Polymer 52(13) (2011) 2799-2809.##[77] T. Boulikas, Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts, Oncology reports 12(1) (2004) 3-12. ##[78] J. Conde, G. Doria, P. Baptista, Noble metal nanoparticles applications in cancer, Journal of drug delivery 2012 (2012).##[79] Y.-H. Chen, C.-Y. Tsai, P.-Y. Huang, M.-Y. Chang, P.-C. Cheng, C.-H. Chou, D.-H. Chen, C.-R. Wang, A.-L. Shiau, C.-L. Wu, Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model, Molecular pharmaceutics 4(5) (2007) 713-722. ##[80] H. Rajpurohit, P. Sharma, S. Sharma, A. Bhandari, Polymers for colon targeted drug delivery, Indian J Pharm Sci 72(6) (2010) 689-96.## [81] P. Mukhopadhyay, A. Prajapati, Quercetin in anti-diabetic research and strategies for improved quercetin bioavailability using polymer-based carriers–a review,RSC advances 5(118) (2015) 97547-97562.## [82] Z. Izadi, A. Divsalar, A.A. Saboury, L. Sawyer, β‐lactoglobulin–pectin Nanoparticle‐based Oral Drug Delivery System for Potential Treatment of Colon Cancer, Chemical biology and drug design 88(2) (2016) 209-216.##[83] O. Jones, E.A. Decker, D.J. McClements, Thermal analysis of β-lactoglobulin complexes with pectins or carrageenan for production of stable biopolymer particles, Food Hydrocolloids 24(2-3) (2010) 239-248.##[84] V. Ravi, T.P. Kumar, Novel colon targeted drug delivery system using natural polymers, Indian journal of pharmaceutical sciences 70(1) (2008) 111.##[85] M. Lorenzo-Lamosa, C. Remunan-Lopez, J. Vila-Jato, M. Alonso, Design of microencapsulated chitosan microspheres for colonic drug delivery, Journal of controlled release 52(1-2) (1998) 109-118. ##[86] Y. Ren, R. Wang, L. Gao, K. Li, X. Zhou, H. Guo, C. Liu, D. Han, J. Tian, Q. Ye, Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy, Journal of Controlled Release 228 (2016) 74-86.##[87] H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J.I. Zink, A.E. Nel, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS nano 4(8)(2010)4539-4550.##[88] N. Olov, S. Bagheri‐Khoulenjani, H. Mirzadeh, Combinational drug delivery using nanocarriers for breast cancer treatments: A review, Journal of Biomedical Materials Research Part A 106(8) (2018) 2272-2283.##[89] N. Mohtar, T. Parumasivam, A.M. Gazzali, C.S. Tan, M.L. Tan, R. Othman, S.S. Fazalul Rahiman, H.A. Wahab, Advanced nanoparticle-based drug delivery systems and their cellular evaluation for non-small cell lung cancer treatment, Cancers 13(14) (2021) 3539.##[90] A. Crintea, A.G. Dutu, G. Samasca, I.A. Florian, I. Lupan, A.M. Craciun, The nanosystems involved in treating lung cancer, Life 11(7) (2021) 682.##[91] B. Tian, S. Liu, S. Wu, W. Lu, D. Wang, L. Jin, B. Hu, K. Li, Z. Wang, Z.Quan, pH-responsive poly (acrylic acid)-gated mesoporous silica and its application in oral colon targeted drug delivery for doxorubicin, Colloids and Surfaces B: Biointerfaces 154 (2017) 287-296.##[92] A.L. Theiss, H. Laroui, T.S. Obertone, I. Chowdhury, W.E. Thompson, D.Merlin, S.V. Sitaraman, Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis, Inflammatory bowel diseases 17(5) (2011) 1163-1176.##[93] S. Khan, A.A. Ansari, A. Malik, A.A. Chaudhary, J.B. Syed, A.A. Khan, Preparation, characterizations and in vitro cytotoxic activity of nickel oxide nanoparticles on HT-29 and SW620 colon cancer cell lines, Journal of Trace Elements in Medicine and Biology 52 (2019) 12-17.##[94] S. Mannucci, L. Ghin, G. Conti, S. Tambalo, A. Lascialfari, T. Orlando, D.Benati, P. Bernardi, N. Betterle, R. Bassi, Magnetic nanoparticles from Magnetospirillum gryphiswaldense increase the efficacy of thermotherapy in a model of colon carcinoma, PloS one 9(10) (2014) e108959.##[95] M. Creixell, A.P. Herrera, V. Ayala, M. Latorre-Esteves, M. Perez-Torres, M.Torres-Lugo, C. Rinaldi, Preparation of epidermal growth factor (EGF) conjugatediron oxide nanoparticles and their internalization into colon cancer cells, Journal of Magnetism and Magnetic Materials 322(15) (2010) 2244-2250.##[96] Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, H. Dai, Drug delivery with carbon nanotubes for in vivo cancer treatment, Cancer research 68(16) (2008) 6652-6660.##[97] P.-C. Lee, Y.-C. Chiou, J.-M. Wong, C.-L. Peng, M.-J. Shieh, Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody, Biomaterials 34(34) (2013) 8756-8765. ##[98] N. Belali, N. Wathoni, M. Muchtaridi, Advances in orally targeted drug delivery to colon, Journal of advanced pharmaceutical technology and research 10(3)(2019) 100.##[99] J.S. Butler, P.J. Sadler, Targeted delivery of platinum-based anticancer complexes, Current Opinion in Chemical Biology 17(2) (2013) 175-188. ##[100] P. Ma, R.J. Mumper, Paclitaxel nano-delivery systems: a comprehensive review, Journal of nanomedicine and nanotechnology 4(2) (2013) 1000164.##[101] V. Koutu, M. Gupta, S. Das, D.K. Rawat, V. Kharade, R.K. Pasricha, R. Pasricha, Nanotechnology in Lung Cancer Therapeutics: A Narrative Review, Cureus 15(1) (2023). ##[102] E. Carrasco-Esteban, J.A. Domínguez-Rullán, P. Barrionuevo-Castillo, L.Pelari-Mici, O. Leaman, S. Sastre-Gallego, F. López-Campos, Current role of nanoparticles in the treatment of lung cancer, Journal of Clinical and Translational Research 7(2) (2021) 140.##[103] B. Buyana, T. Naki, S. Alven, B.A. Aderibigbe, Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy, Int J Mol Sci 23(19) (2022)##[104] N.J. Wheate, J.G. Collins, Multi-nuclear platinum drugs: a new paradigm in chemotherapy, Current Medicinal Chemistry-Anti-Cancer Agents 5(3) (2005) 267-279. ##[105] D. Lombardo, M.A. Kiselev, M.T. Caccamo, Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine, Journal of nanomaterials 2019 (2019).##[106] U. Dristant, K. Mukherjee, S. Saha, D. Maity, An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment, Technology in Cancer Research and Treatment 22 (2023) 15330338231152083.##[107] L. Zhang, J.M. Chan, F.X. Gu, J.-W. Rhee, A.Z. Wang, A.F. Radovic-More-no, F. Alexis, R. Langer, O.C. Farokhzad, Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform, ACS nano 2(8) (2008) 1696-1702.##[108] A.E. LaBauve, T.E. Rinker, A. Noureddine, R.E. Serda, J.Y. Howe, M.B. Sherman, A. Rasley, C.J. Brinker, D.Y. Sasaki, O.A. Negrete, Lipid-coated mesoporous silica nanoparticles for the delivery of the ML336 antiviral to inhibit encephalitic alphavirus infection, Scientific reports 8(1) (2018) 13990.##[109] J.Y. Choi, T. Ramasamy, S.Y. Kim, J. Kim, S.K. Ku, Y.S. Youn, J.-R. Kim, J.- H. Jeong, H.-G. Choi, C.S. Yong, PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy, Acta biomaterialia 39 (2016) 94-105.##[110] A. Chowdhury, S. Kunjiappan, T. Panneerselvam, B. Somasundaram, C.Bhattacharjee, Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases, International nano letters 7 (2017) 91-122.##[111] A. Mahzabin, B. Das, A review of lipid-polymer hybrid nanoparticles as a new generation drug delivery system, Int. J. Pharm. Sci. Res 12 (2021) 65-75.##[112] R.X. Zhang, T. Ahmed, L.Y. Li, J. Li, A.Z. Abbasi, X.Y. Wu, Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks, Nanoscale 9(4) (2017) 1334-1355.##[113] C.J. Hitzman, W.F. Elmquist, L.W. Wattenberg, T.S. Wiedmann, Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles, Journal of pharmaceutical sciences 95(5) (2006) 1114-1126. ##[114] K.K. Gill, S. Nazzal, A. Kaddoumi, Paclitaxel loaded PEG5000–DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation, European Journal of Pharmaceutics and Biopharmaceutics 79(2) (2011) 276-284.##[115] Y. Perrie, Gregory Gregoriadis: Introducing liposomes to drug delivery, Journal of Drug Targeting 16(7-8) (2008) 518-519.## [116] L.-L. Bu, J. Yan, Z. Wang, H. Ruan, Q. Chen, V. Gunadhi, R.B. Bell, Z. Gu, Advances in drug delivery for post-surgical cancer treatment, Biomaterials 219 (2019) 119182. ##[117] E. Muntimadugu, N. Kommineni, W. Khan, Exploring the potential of nan-otherapeutics in targeting tumor microenvironment for cancer therapy, Pharmacological Research 126 (2017) 109-122.